Literature DB >> 15016912

Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors.

Chih-Cheng Tsai1, Hung-Ying Kao, Akifumi Mitzutani, Ester Banayo, Harini Rajan, Michael McKeown, Ronald M Evans.   

Abstract

Ataxin 1 (Atx1) is a foci-forming polyglutamine protein of unknown function, whose mutant form causes type 1 spinocerebellar ataxia in humans and exerts neurotoxicity in transgenic mouse and fly expressing mutant Atx1. In this study, we demonstrate that Atx1 interacts with the transcriptional corepressor SMRT (silencing mediator of retinoid and thyroid hormone receptors) and with histone deacetylase 3. Atx1 binds chromosomes and mediates transcriptional repression when tethered to DNA. Interaction with SMRT-related factors is a conserved feature of Atx1, because Atx1 also binds SMRTER, a Drosophila cognate of SMRT. Significantly, mutant Atx1 forms aggregates in Drosophila, and such mutant Atx1-mediated aggregates sequester SMRTER. Consistently, the neurodegenerative eye phenotype caused by mutant Atx1 is enhanced by a Smrter mutation and, conversely, is suppressed by a chromosomal duplication that contains the wild type Smrter gene. Together, our results suggest that Atx1 is a transcriptional factor whose mutant form exerts its deleterious effects in part by perturbing corepressor-dependent transcriptional pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016912      PMCID: PMC384693          DOI: 10.1073/pnas.0400615101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Unique forms of human and mouse nuclear receptor corepressor SMRT.

Authors:  P Ordentlich; M Downes; W Xie; A Genin; N B Spinner; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  A transcriptional co-repressor that interacts with nuclear hormone receptors.

Authors:  J D Chen; R M Evans
Journal:  Nature       Date:  1995-10-05       Impact factor: 49.962

3.  The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1.

Authors:  A Matilla; B T Koshy; C J Cummings; T Isobe; H T Orr; H Y Zoghbi
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

4.  SMRTER, a Drosophila nuclear receptor coregulator, reveals that EcR-mediated repression is critical for development.

Authors:  C C Tsai; H Y Kao; T P Yao; M McKeown; R M Evans
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

5.  Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.

Authors:  J K Cooper; G Schilling; M F Peters; W J Herring; A H Sharp; Z Kaminsky; J Masone; F A Khan; M Delanoy; D R Borchelt; V L Dawson; T M Dawson; C A Ross
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

6.  Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1.

Authors:  C J Cummings; M A Mancini; B Antalffy; D B DeFranco; H T Orr; H Y Zoghbi
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

7.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  The influence of huntingtin protein size on nuclear localization and cellular toxicity.

Authors:  A S Hackam; R Singaraja; C L Wellington; M Metzler; K McCutcheon; T Zhang; M Kalchman; M R Hayden
Journal:  J Cell Biol       Date:  1998-06-01       Impact factor: 10.539

9.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin.

Authors:  J M Boutell; P Thomas; J W Neal; V J Weston; J Duce; P S Harper; A L Jones
Journal:  Hum Mol Genet       Date:  1999-09       Impact factor: 6.150

10.  Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures.

Authors:  P J Skinner; B T Koshy; C J Cummings; I A Klement; K Helin; A Servadio; H Y Zoghbi; H T Orr
Journal:  Nature       Date:  1997-10-30       Impact factor: 49.962

View more
  59 in total

Review 1.  Nuclear ataxias.

Authors:  Harry T Orr
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

Review 2.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 3.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

4.  Functional interactions with Pit-1 reorganize co-repressor complexes in the living cell nucleus.

Authors:  Ty C Voss; Ignacio A Demarco; Cynthia F Booker; Richard N Day
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

5.  Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.

Authors:  Scoty M Hearst; Mariper E Lopez; Qingmei Shao; Yong Liu; Parminder J S Vig
Journal:  J Neurochem       Date:  2010-04-30       Impact factor: 5.372

6.  Ataxin active site determination using spectral distribution of electron ion interaction potentials of amino acids.

Authors:  E Pirogova; V Vojisavljevic; J L Hernández Cáceres; I Cosic
Journal:  Med Biol Eng Comput       Date:  2010-02-11       Impact factor: 2.602

7.  Atrophin recruits HDAC1/2 and G9a to modify histone H3K9 and to determine cell fates.

Authors:  Lei Wang; Bernard Charroux; Stephen Kerridge; Chih-Cheng Tsai
Journal:  EMBO Rep       Date:  2008-05-02       Impact factor: 8.807

Review 8.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

Review 9.  Polyglutamine spinocerebellar ataxias - from genes to potential treatments.

Authors:  Henry L Paulson; Vikram G Shakkottai; H Brent Clark; Harry T Orr
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

10.  LANP mediates neuritic pathology in Spinocerebellar ataxia type 1.

Authors:  Marija Cvetanovic; Rupinder K Kular; Puneet Opal
Journal:  Neurobiol Dis       Date:  2012-08-04       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.